Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) and Senesco Technologies (OTCMKTS:SVON) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Profitability

This table compares Jazz Pharmaceuticals PLC and Senesco Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Jazz Pharmaceuticals PLC 25.69% 22.75% 9.14%
Senesco Technologies N/A -68.96% -33.63%

Risk and Volatility

Jazz Pharmaceuticals PLC has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Senesco Technologies has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Jazz Pharmaceuticals PLC and Senesco Technologies, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jazz Pharmaceuticals PLC 0 5 15 0 2.75
Senesco Technologies 0 0 0 0 N/A

Jazz Pharmaceuticals PLC presently has a consensus target price of $181.20, suggesting a potential upside of 28.17%. Given Jazz Pharmaceuticals PLC’s higher probable upside, equities research analysts plainly believe Jazz Pharmaceuticals PLC is more favorable than Senesco Technologies.

Valuation and Earnings

This table compares Jazz Pharmaceuticals PLC and Senesco Technologies’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Jazz Pharmaceuticals PLC $1.54 billion 5.51 $758.97 million $6.45 21.92
Senesco Technologies N/A N/A -$2.26 million ($0.24) -0.98

Jazz Pharmaceuticals PLC has higher revenue and earnings than Senesco Technologies. Senesco Technologies is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals PLC, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

88.3% of Jazz Pharmaceuticals PLC shares are held by institutional investors. 4.3% of Jazz Pharmaceuticals PLC shares are held by insiders. Comparatively, 25.1% of Senesco Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Jazz Pharmaceuticals PLC beats Senesco Technologies on 9 of the 11 factors compared between the two stocks.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).

Senesco Technologies Company Profile

Sevion Therapeutics, Inc. is a development-stage biotech company. The Company is engaged in building and developing a portfolio of therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company is engaged in the development and licensing of technology to discover and engineer monoclonal antibodies. The Company’s product candidates are derived from multiple technology platforms, such as cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. The Company has various antibodies in its preclinical pipeline. The Company’s antibody therapeutic candidates target the potassium channel, voltage dependent (Kv1.3) ion channel, which is essential in the pathogenesis of several autoimmune and inflammatory disorders. Other antibodies in its pipeline target cell surface molecules involved in cancer progression.

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.